68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02481726|
Recruitment Status : Completed
First Posted : June 25, 2015
Last Update Posted : June 25, 2015
Information provided by (Responsible Party):
Comparison of 68Ga-AlfatideII and 18F-FDG in differential diagnosis effectiveness towards the solitary pulmonary nodules of lung cancer or tuberculosis.
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer Lung Tuberculosis||Radiation: 68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||31 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||March 2014|
|Actual Primary Completion Date :||October 2014|
Resource links provided by the National Library of Medicine
In patients in suspicion of lung cancer or lung tuberculosis; in patients with differential diagnosis difficulties; without treatment or surgery. They underwent a standard routine 18F-FDG PET/CT first, and were injected 10~20MBq 68Ga-Alfatide II in the next day, followed by whole body PET/CT acquisitions.
Radiation: 68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG
Primary Outcome Measures :
- Quantitative measurement of standardized uptake values (SUVs) of lesions. [ Time Frame: 1 year ]The quantitative analysis will be performed by the same person for all cases, and the standardized uptake value (SUV) of each tumor will be measured using a volume of interest (VOI) method.
Secondary Outcome Measures :
- Number of participants with adverse events as a measure of safety after 68Ga-NEB injection and PET/CT scanning. [ Time Frame: 1 year ]
No Contacts or Locations Provided